Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pedi...
What are the risks highlighted in the MD&A (e.g., regulatory, manufacturing, competition) that could affect the stock’s risk profile?
How does the sentiment rating of 10 align with analyst consensus and recent market sentiment for LGVN?
What is the potential dilution risk from upcoming equity offerings or convertible securities disclosed in the filing?
26 days ago